Compare NVMI & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVMI | RVMD |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 15.2B |
| IPO Year | 2001 | N/A |
| Metric | NVMI | RVMD |
|---|---|---|
| Price | $432.45 | $99.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $427.14 | $114.63 |
| AVG Volume (30 Days) | 353.7K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.69 | N/A |
| Revenue Next Year | $19.45 | $552.08 |
| P/E Ratio | $56.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $154.00 | $29.17 |
| 52 Week High | $507.27 | $124.49 |
| Indicator | NVMI | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 48.16 |
| Support Level | $427.67 | $93.59 |
| Resistance Level | $473.57 | $107.45 |
| Average True Range (ATR) | 17.63 | 3.70 |
| MACD | -4.44 | -0.42 |
| Stochastic Oscillator | 46.54 | 34.06 |
Nova Ltd is a provider of metrology and process control solutions used in semiconductor manufacturing. The company provides high-performance metrology solutions across the semiconductor fabrication lifecycle and develops differentiated inline metrology solutions deployed by a broad range of customers, including integrated circuit manufacturers. Its portfolio combines high-precision hardware and software, enabling customers to improve device performance, enhance yields, and accelerate time to market. Its products include Dimensional Metrology, Materials Metrology, Chemical Metrology, and Software Solutions. The company operates in China, Taiwan, R.O.C., the United States and other regions, with maximum revenue coming from China.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.